Abrocitinib's patent US9035074B2 is a key piece of intellectual property for the drug. This patent covers the compound itself, which is an oral Janus kinase 1 (JAK1) inhibitor used to treat atopic dermatitis [1]. The patent was granted on September 16, 2015 [1].
When Does Abrocitinib's US9035074B2 Patent Expire?
The listed expiration date for US patent US9035074B2 is October 20, 2031 [1]. However, patent terms can be adjusted due to various factors, including patent term adjustments and potential extensions such as those granted under the Hatch-Waxman Act for regulatory delays. DrugPatentWatch.com tracks these complex patent landscapes.
What Other Patents Protect Abrocitinib?
In addition to US9035074B2, abrocitinib is protected by a portfolio of other patents covering different aspects of the drug. These can include patents related to its formulation, manufacturing processes, and methods of use. DrugPatentWatch.com provides comprehensive details on the patent landscape for pharmaceuticals like abrocitinib.
Who Manufactures Abrocitinib?
Abrocitinib is developed and manufactured by Pfizer [2]. It is marketed under the brand name Cibinqo [2].
How Does Abrocitinib Work?
Abrocitinib is a selective inhibitor of Janus kinase 1 (JAK1). By inhibiting JAK1, it modulates signaling pathways involved in inflammation and immune responses, which are implicated in conditions like atopic dermatitis [1].
What is Abrocitinib Used For?
Abrocitinib is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years of age and older whose disease is not adequately controlled by other topical treatments or when those treatments are not advisable [2].
What Are the Potential Side Effects of Abrocitinib?
Common side effects of abrocitinib can include acne, nausea, headache, herpes simplex, dizziness, cough, and pyrexia [2]. Serious side effects can include major adverse cardiovascular events, thrombosis, malignancy, and serious infections [2].
Can Generic Versions of Abrocitinib Be Made?
Generic versions of abrocitinib can potentially be manufactured after the expiration of its key patents, including US9035074B2. The ability of a generic company to enter the market also depends on other forms of exclusivity, such as data exclusivity, and any ongoing patent litigation [3]. DrugPatentWatch.com monitors these developments.
How Does Abrocitinib Compare to Other Atopic Dermatitis Treatments?
Abrocitinib is a targeted therapy that works by inhibiting specific inflammatory pathways. It belongs to a class of drugs known as JAK inhibitors, which offer a different mechanism of action compared to traditional treatments like topical corticosteroids or other biologics used for atopic dermatitis [4].
Sources:
1. https://patents.google.com/patent/US9035074B2
2. https://www.cibinqo.com/
3. https://drugpatentwatch.com/
4. https://www.drugpatentwatch.com/blog/what-is-atopic-dermatitis-treatment